Claudia Luna-Herrera
Research Subjects
Claudia Luna-Herrera has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bertha Alicia Leon-Chavez
Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 sur y Av. San Claudio, 72570 Puebla, PUE, Mexico
2 shared publications - Daniel Martinez-Fong
Departamento de Fisiología, Biofísica y Neurociencias, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. I.P.N. No. 2508, 07360 Ciudad de México, Mexico; Nanoparticle Therapy Institute, 404 Avenida Monte Blanco, 20120 Aguascalientes, Mexico
2 shared publications - David Reyes-Corona
Departamento de Fisiologia
2 shared publications - Irma A. Martínez-Dávila
Departamento de Fisiologia
2 shared publications - Jose Ayala-Davila
Departamento de Fisiologia
2 shared publications - Luis Oskar Soto Rojas
Universidad Nacional Autónoma de México, Facultad de Estudios Superiores Iztacala
2 shared publications
Latest Publications
- Open Access
- 1 January 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020 (1)
Intranigral Administration of β ‐Sitosterol‐ β ‐D‐Glucoside Elicits Neurotoxic A1 Astrocyte Reactivity and Chronic Neuroinflammation in the Rat Substantia Nigra
Chronic consumption of β ‐sitosterol‐ β ‐D‐glucoside (BSSG), a neurotoxin contained in cycad seeds, leads to Parkinson’s disease in humans and rodents. Here, we explored whether a single intranigral administration of BSSG triggers neuroinflammation and neurotoxic A1 reactive astrocytes besides dopaminergic neurodegeneration. We injected 6 μ g BSSG/1 μ L DMSO or vehicle into the left substantia nigra and immunostained with antibodies against tyrosine hydroxylase (TH) together with markers of microglia (OX42), astrocytes (GFAP, S100 β , C3), and leukocytes (CD45). We also measured nitric oxide (NO), lipid peroxidation (LPX), and proinflammatory cytokines (TNF‐ α , IL‐1 β , IL‐6). The Evans blue assay was used to explore the blood‐brain barrier (BBB) permeability. We found that BSSG activates NO production on days 15 and 30 and LPX on day 120. Throughout the study, high levels of TNF‐ α were present in BSSG‐treated animals, whereas IL‐1 β was induced until day 60 and IL‐6 until day 30. Immunoreactivity of activated microglia (899.0 ± 80.20 % ) and reactive astrocytes (651.50 ± 11.28 % ) progressively increased until day 30 and then decreased to remain 251.2 ± 48.8 % (microglia) and 91.02 ± 39.8 (astrocytes) higher over controls on day 120. C3(+) cells were also GFAP and S100 β immunoreactive, showing they were neurotoxic A1 reactive astrocytes. BBB remained permeable until day 15 when immune cell infiltration was maximum. TH immunoreactivity progressively declined, reaching 83.6 ± 1.8 % reduction on day 120. Our data show that BSSG acute administration causes chronic neuroinflammation mediated by activated microglia, neurotoxic A1 reactive astrocytes, and infiltrated immune cells. The severe neuroinflammation might trigger Parkinson’s disease in BSSG intoxication.
- 1 January 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020 (1)
Open AccessIntranigral Administration of β ‐Sitosterol‐ β ‐D‐Glucoside Elicits Neurotoxic A1 Astrocyte Reactivity and Chronic Neuroinflammation in the Rat Substantia Nigra
Chronic consumption of β ‐sitosterol‐ β ‐D‐glucoside (BSSG), a neurotoxin contained in cycad seeds, leads to Parkinson’s disease in humans and rodents. Here, we explored whether a single intranigral administration of BSSG triggers neuroinflammation and neurotoxic A1 reactive astrocytes besides dopaminergic neurodegeneration. We injected 6 μ g BSSG/1 μ L DMSO or vehicle into the left substantia nigra and immunostained with antibodies against tyrosine hydroxylase (TH) together with markers of microglia (OX42), astrocytes (GFAP, S100 β , C3), and leukocytes (CD45). We also measured nitric oxide (NO), lipid peroxidation (LPX), and proinflammatory cytokines (TNF‐ α , IL‐1 β , IL‐6). The Evans blue assay was used to explore the blood‐brain barrier (BBB) permeability. We found that BSSG activates NO production on days 15 and 30 and LPX on day 120. Throughout the study, high levels of TNF‐ α were present in BSSG‐treated animals, whereas IL‐1 β was induced until day 60 and IL‐6 until day 30. Immunoreactivity of activated microglia (899.0 ± 80.20 % ) and reactive astrocytes (651.50 ± 11.28 % ) progressively increased until day 30 and then decreased to remain 251.2 ± 48.8 % (microglia) and 91.02 ± 39.8 (astrocytes) higher over controls on day 120. C3(+) cells were also GFAP and S100 β immunoreactive, showing they were neurotoxic A1 reactive astrocytes. BBB remained permeable until day 15 when immune cell infiltration was maximum. TH immunoreactivity progressively declined, reaching 83.6 ± 1.8 % reduction on day 120. Our data show that BSSG acute administration causes chronic neuroinflammation mediated by activated microglia, neurotoxic A1 reactive astrocytes, and infiltrated immune cells. The severe neuroinflammation might trigger Parkinson’s disease in BSSG intoxication.
- Open Access
- 8 May 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-19
Acute Neuroinflammatory Response in the Substantia Nigra Pars Compacta of Rats after a Local Injection of Lipopolysaccharide
Models of Parkinson’s disease with neurotoxins have shown that microglial activation does not evoke a typical inflammatory response in the substantia nigra, questioning whether neuroinflammation leads to neurodegeneration. To address this issue, the archetypal inflammatory stimulus, lipopolysaccharide (LPS), was injected into the rat substantia nigra. LPS induced fever, sickness behavior, and microglial activation (OX42 immunoreactivity), followed by astrocyte activation and leukocyte infiltration (GFAP and CD45 immunoreactivities). During the acute phase of neuroinflammation, pro- and anti-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-4, and IL-10) responded differentially at mRNA and protein level. Increased NO production and lipid peroxidation occurred at 168 h after LPS injection. At this time, evidence of neurodegeneration could be seen, entailing decreased tyrosine hydroxylase (TH) immunoreactivity, irregular body contour, and prolongation discontinuity of TH+cells, as well as apparent phagocytosis of TH+cells by OX42+cells. Altogether, these results show that LPS evokes a typical inflammatory response in the substantia nigra that is followed by dopaminergic neurodegeneration.
- 8 May 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-19
Open AccessAcute Neuroinflammatory Response in the Substantia Nigra Pars Compacta of Rats after a Local Injection of Lipopolysaccharide
Models of Parkinson’s disease with neurotoxins have shown that microglial activation does not evoke a typical inflammatory response in the substantia nigra, questioning whether neuroinflammation leads to neurodegeneration. To address this issue, the archetypal inflammatory stimulus, lipopolysaccharide (LPS), was injected into the rat substantia nigra. LPS induced fever, sickness behavior, and microglial activation (OX42 immunoreactivity), followed by astrocyte activation and leukocyte infiltration (GFAP and CD45 immunoreactivities). During the acute phase of neuroinflammation, pro- and anti-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-4, and IL-10) responded differentially at mRNA and protein level. Increased NO production and lipid peroxidation occurred at 168 h after LPS injection. At this time, evidence of neurodegeneration could be seen, entailing decreased tyrosine hydroxylase (TH) immunoreactivity, irregular body contour, and prolongation discontinuity of TH+cells, as well as apparent phagocytosis of TH+cells by OX42+cells. Altogether, these results show that LPS evokes a typical inflammatory response in the substantia nigra that is followed by dopaminergic neurodegeneration.